MSD Of India Defends Marketing Of Gardasil Against Cervical Cancer
This article was originally published in PharmAsia News
India's MSD Pharmaceuticals Private says its marketing of Gardasil vaccine, approved to prevent the human papilloma virus, for other uses is justified given 10 years of research and development
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.